Leukemia Treatment Breakthrough
Adding Rituxan to standard chemotherapy for chronic lymphocytic leukemia raises three-year survival to 65% and is now the gold standard therapy for most patients.
Click here to read the full story.
The content has been reported and it will be reviewed by a moderator.